Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases

Trends in Pharmacological Sciences

Volumn 31, Issue 5, 2010, Pages 199-205

  Godin, Biana ^a   Sakamoto, Jason H ^a   Serda, Rita E ^a   Grattoni, Alessandro ^a   Bouamrani, Ali ^a   Ferrari, Mauro ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CHLORAMPHENICOL ACETYLTRANSFERASE; CLODRONIC ACID; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FERUMOXSIL; GADOLINIUM PENTETATE; GOLD NANOPARTICLE; IODINE; LIPOSOME; NANOPARTICLE; NANOSHELL; PACLITAXEL; POLYETHYLENEIMINE; POLYGLACTIN; POLYLACTIC ACID; QUANTUM DOT; STEROID; STREPTOKINASE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TISSUE FACTOR PATHWAY INHIBITOR; TYRPHOSTIN; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY OCCLUSION; ATHEROSCLEROSIS; BIOSENSOR; CARDIOVASCULAR DISEASE; CAROTID ARTERY INJURY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; EARLY DIAGNOSIS; EQUIPMENT DESIGN; HEART INFARCTION; HUMAN; LAB ON A CHIP; LIPOSOMAL GENE DELIVERY SYSTEM; MICROELECTROMECHANICAL SYSTEM; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; DRUG-ELUTING STENTS; EARLY DIAGNOSIS; HUMANS; NANOMEDICINE; NANOPARTICLES;

EID: 77952551701     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.01.003     Document Type: Review

References (86)

1. Theis T., et al. nan'o.tech.nol'o.gy n. Nat. Nanotechnol. 2006, 1:8-10.
2. Riehemann K., et al. Nanomedicine-challenge and perspectives. Angew Chem. Int. Ed. Engl. 2009, 48:872-897.
3. Kong D.F., Goldschmidt-Clermont P.J. Tiny solutions for giant cardiac problems. Trends Cardiovasc. Med 2005, 15:207-211.
4. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
5. Peer D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
6. Ferrari M. Nanogeometry: beyond drug delivery. Nat. Nanotechnol. 2008, 3:131-132.
7. Smith R.C., McCarthy S. Physics of magnetic resonance. J. Reprod. Med. 1992, 37:19-26.
8. Cunningham C.H., et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 2005, 53:999-1005.
9. Sosnovik D.E., et al. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res. Cardiol. 2008, 103:122-130.
10. Pan D., et al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem. Commun. (Camb.) 2009, 22:3234-3236.
11. Pan D., et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem. Soc. 2008, 130:9186-9187.
12. Michalet X., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
13. Serda R.E., et al. Mitotic trafficking of silicon microparticles. Nanoscale 2009, 1:250-259.
14. Kooi M.E., et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107:2453-2458.
15. Devaraj N.K., et al. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug. Chem. 2009, 20:397-401.
16. Nahrendorf M., et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
17. Chen W., et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 2008, 3:233-242.
18. Kao C.Y., et al. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad. Radiol. 2003, 10:475-483.
19. Mukundan S., et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am. J. Roentgenol. 2006, 186:300-307.
20. Pan D., et al. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J. Am. Chem. Soc. 2009, 131:15522-15527.
21. Corot C., et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 2006, 58:1471-1504.
22. Amirbekian V., et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl. Acad. Sci. U S A 2007, 104:961-966.
23. Botnar R.M., et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004, 110:1463-1466.
24. Cyrus T., et al. MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J. Cardiovasc. Magn. Reson. 2006, 8:535-541.
25. Lanza G.M., et al. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J. Acoust. Soc. Am. 1998, 104:3665-3672.
26. Morawski A.M., et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 2004, 51:480-486.
27. Winter P.M., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
28. Brito L., Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int. J. Nanomedicine 2007, 2:143-161.
29. Buxton D.B. Nanomedicine for the management of lung and blood diseases. Nanomedicine 2009, 4:331-339.
30. Danenberg H.D., et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002, 106:599-605.
31. Stephan D., et al. Direct gene transfer in the rat kidney in vivo. Arch. Mal. Coeur Vaiss 1997, 90:1127-1130. [In French].
32. Hedman M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683.
33. Lanza G.M., et al. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 2006, 1:321-329.
34. Jaffer F.A., et al. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1017-1024.
35. Cyrus T., et al. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vasc. Biol. 2008, 28:820-826.
36. Winter P.M., et al. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging 2008, 1:624-634.
37. Winter P.M., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2103-2219.
38. Marsh J.N., et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2007, 2:533-543.
39. Lukyanenko V. Delivery of nano-objects to functional sub-domains of healthy and failing cardiac myocytes. Nanomedicine 2007, 2:831-846.
40. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
41. Danesh J., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004, 350:1387-1397.
42. Wang T.J., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 2004, 350:655-663.
43. Danesh J., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
44. Cushman M., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 1999, 19:493-498.
45. Mangoni A.A., Jackson S.H. Homocysteine and cardiovascular disease: current evidence and future prospects. Am. J. Med. 2002, 112:556-565.
46. Wang T.J., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006, 355:2631-2639.
47. Gaspari M., et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J. Proteome Res. 2006, 5:1261-1266.
48. Luchini A., et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano. Lett. 2008, 8:350-361.
49. Cui Y., et al. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001, 293:1289-1292.
50. McKendry R., et al. Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proc. Natl. Acad. Sci. U S A 2002, 99:9783-9788.
51. McMurray A.A., et al. A novel point of care diagnostic device: impedimetric detection of a biomarker in whole blood. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2007, 115-118.
52. Floriano P.N., et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin. Chem. 2009, 55:1530-1538.
53. Wang J., et al. Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology. Adv. Exp. Med. Biol. 2009, 645:101-107.
54. Jaffe A.S., et al. It's time for a change to a troponin standard. Circulation 2000, 102:1216-1220.
55. Wilson S.R., et al. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am. Heart J. 2009, 158:386-391.
56. Park J.S., et al. A highly sensitive and selective diagnostic assay based on virus nanoparticles. Nat. Nanotechnol. 2009, 4:259-264.
57. Vogt S., et al. Efficacy of ion-selective probes in early epicardial in vivo detection of myocardial ischemia. Physiol. Meas. 2004, 25:N21-26.
58. Ji T., et al. In vitro evaluation of flexible pH and potassium ion-sensitive organic field effect transistor sensors. Appl. Phys. Lett. 2008, 92:233-304.
59. Errachid A., et al. New technology for multi-sensor silicon needles for biomedical applications. Sensors Actuators B: Chem. 2001, 78:279-284.
60. Dubach J.M., et al. Visualizing sodium dynamics in isolated cardiomyocytes using fluorescent nanosensors. Proc. Natl. Acad. Sci. U S A 2009, 106:16145-16150.
61. Kim J.-H., et al. The rational design of nitric oxide selectivity in single-walled carbon nanotube near-infrared fluorescence sensors for biological detection. Nat. Chem. 2009, 1:473-481.
62. Sato M., et al. Cell-based indicator to visualize picomolar dynamics of nitric oxide release from living cells. Anal. Chem. 2006, 78:8175-8182.
63. Rouhanizadeh M., et al. Differentiation of oxidized low density lipoproteins by nanosensors. Sensors Actuators B: Chem. 2006, 114:788-798.
64. Kovacs G.T.A. Micromachined Transducers Handbook. 1998, McGraw Hill, New York.
65. Shin K.H., et al. Flexible wireless pressure sensor module. Sensors Actuators A. 2005, 123-124:30-35.
66. Hoffmann R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996, 94:1247-1254.
67. Samaroo H.D., et al. Enhanced endothelial cell density on NiTi surfaces with sub-micron to nanometer roughness. Int. J. Nanomedicine 2008, 3:75-82.
68. Kastrati A., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 2007, 356:1030-1039.
69. Lagerqvist B., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007, 356:1009-1019.
70. Mauri L., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 2007, 356:1020-1029.
71. Stone G.W., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 2007, 356:998-1008.
72. Wieneke H., et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc. Interv. 2003, 60:399-407.
73. Bhargava B., et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc. Interv. 2006, 67:698-702.
74. Erlebacher J., et al. Evolution of nanoporosity in dealloying. Nature 2001, 410:450-453.
75. 2 films. Biomed. Mater. 2006, 1:L11-L15.
76. Liu D.M., et al. Sol-gel hydroxyapatite coatings on stainless steel substrates. Biomaterials 2002, 23:691-698.
77. Caves J.M., Chaikof E.L. The evolving impact of microfabrication and nanotechnology on stent design. J. Vasc. Surg. 2006, 44:1363-1368.
78. Kim D., et al. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J. Am. Chem. Soc. 2007, 129:7661-7665.
79. Hyafil F., et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 2007, 13:636-641.
80. Pan D., et al. Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem. Int. Ed. Engl. 2009, 48:4170-4173.
81. Loo C., et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer Res. Treat. 2004, 3:33-40.
82. Kaneda M.M., et al. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng. 2009, 37:1922-1933.
83. Yin X., et al. HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. Int. J. Cardiol. 2009, 135:245-248.
84. Zaitsev S., et al. Polyelectrolyte nanoparticles mediate vascular gene delivery. Pharm. Res. 2004, 21:1656-1661.
85. Fishbein I., et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler. Thromb. Vasc. Biol. 2000, 20:667-676.
86. Banai S., et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005, 26:451-461.